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Abstract
Widespread resistance among circulating influenza A strains to at least one of the anti-influenza drugs is a major public
health concern. A triple combination antiviral drug (TCAD) regimen comprised of amantadine, oseltamivir, and ribavirin has
been shown to have synergistic and broad spectrum activity against influenza A strains, including drug resistant strains.
Here, we used mathematical modeling along with three different experimental approaches to understand the effects of
single agents, double combinations, and the TCAD regimen on resistance in influenza in vitro, including: 1) serial passage at
constant drug concentrations, 2) serial passage at escalating drug concentrations, and 3) evaluation of the contribution of
each component of the TCAD regimen to the suppression of resistance. Consistent with the modeling which demonstrated
that three drugs were required to suppress the emergence of resistance in influenza A, treatment with the TCAD regimen
resulted in the sustained suppression of drug resistant viruses, whereas treatment with amantadine alone or the
amantadine-oseltamivir double combination led to the rapid selection of resistant variants which comprised ,100% of the
population. Furthermore, the TCAD regimen imposed a high genetic barrier to resistance, requiring multiple mutations in
order to escape the effects of all the drugs in the regimen. Finally, we demonstrate that each drug in the TCAD regimen
made a significant contribution to the suppression of virus breakthrough and resistance at clinically achievable
concentrations. Taken together, these data demonstrate that the TCAD regimen was superior to double combinations and
single agents at suppressing resistance, and that three drugs at a minimum were required to impede the selection of drug
resistant variants in influenza A virus. The use of mathematical modeling with multiple experimental designs and molecular
readouts to evaluate and optimize combination drug regimens for the suppression of resistance may be broadly applicable
to other infectious diseases.
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Introduction
Combination drug therapies are well established as standard of
care for the treatment of infection by rapidly mutating viruses such
as HIV [1], where resistance arises rapidly to single agents and is
associated with treatment failure [2]. Highly active antiretroviral
therapy consisting of combinations of three or four reverse
transcriptase inhibitors and protease inhibitors has transformed
AIDS into a chronic and manageable disease from a fatal one,
often extending the lifespan of patients by decades [3]. The lessons
learned in HIV were that a combination of drugs with different
mechanisms of action was required for maximal suppression of
replication, resulting in sustained virologic response and reduced
rate of resistance [4,5]. More recently, the development of
combination regimens for the treatment of hepatitis C and
hepatitis B infections demonstrate that the findings from years of
extensive clinical research in HIV may be applicable to other viral
diseases as well [6], including influenza.
Currently there are only two classes of drugs approved for the
treatment of influenza, the neuraminidase inhibitors (NAIs;
oseltamivir and zanamivir) and the M2 channel inhibitors
(amantadine and rimantadine). The 2009 influenza pandemic
highlights the urgent need for new and more effective therapy, and
the emergence of resistance to both drug classes among circulating
influenza A strains has become a major public health concern. In
the 2009–2010 season, 100% of tested H3N2 and 99.8% of the
pandemic 2009 H1N1 subtypes were resistant to M2 channel
inhibitors [7], and nearly 100% of the circulating seasonal H1N1
viruses tested in the 2008–2009 season were resistant to oseltamivir
[8]. In 2009, the seasonal H1N1 viruses were replaced by the
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susceptible to oseltamivir [9]. While resistance to zanamivir has
seldom been detected in the clinic, zanamivir resistant variants
have been generated in cell culture [10,11,12,13].
Treatment with antiviral drugs as single agents may be a
contributing cause to the rise in resistance among influenza
viruses. Oseltamivir-resistant variants have been induced in
patients receiving treatment or chemoprophylaxis with oseltamivir
[14,15], although oseltamivir-resistant seasonal H1N1 viruses have
also arisen in the absence of antiviral drug selection pressure
[16,17]. Given the widespread resistance patterns already existing
among influenza strains, there is concern that monotherapy with
antiviral drugs could lead to the development of dual-resistant
viruses. Multidrug-resistant H3N2 influenza [18] and 2009 H1N1
viruses [19,20] have been isolated from immunocompromised
patients. Because current treatment options are limited for dual-
resistant influenza viruses, continued surveillance of antiviral drug
resistance patterns and the development of new antiviral strategies
are of crucial importance for effective management of influenza
virus infections.
A triple combination antiviral drug (TCAD) regimen com-
prised of amantadine (AMT), oseltamivir (OSC), and ribavirin
(RBV) may be a viable therapeutic option that could address
existing and emerging resistance in influenza A. In previous
studies, TCAD has been shown to have broad spectrum activity
and was synergistic against susceptible and resistant influenza
strains [21,22]. Importantly, the synergy of the TCAD regimen
was greater than any double antiviral drug combination, and
AMT and OSC contributed to the synergy of the TCAD regimen
at concentrations that are clinically achievable against amanta-
dine- and oseltamivir-resistant virus strains, respectively [21].
However, the effect of TCAD on the emergence of resistance has
not been demonstrated to date. Our initial hypothesis was that a
TCAD regimen incorporating drugs with three different
mechanisms of actions is required to effectively reduce the levels
of resistance compared to single and dual-drug therapies. In this
paper, we report modeling results that motivated this effort and
on the effects of TCAD on resistance in vitro by three different
experimental methods: serial passage at constant drug concen-
trations, serial passage at increasing antiviral drug concentrations,
and evaluating the contribution of each component of the TCAD
regimen to the suppression of resistance. We show by all three
methods that the TCAD regimen significantly suppressed the
breakthrough of drug resistant virus in vitro and imposed a high
genetic barrier to resistance compared to single and dual-drug
therapies.
Results
Probability of developing resistance to 1-, 2-, or 3-drug
regimens for influenza A virus
To determine from first principles the number of drugs required
in a regimen to durably suppress the emergence of resistance in
influenza A viruses, we calculated the probability of generating all
possible 1-, 2-, or 3-base changes in the influenza A genome
during the course of an acute infection in healthy individuals that
we assume was initiated by a drug sensitive virus. We make a
number of simplifying assumptions that affect the precise values of
the probabilities we calculate but which do not affect the general
conclusions that we reach. The first assumption was that 1-, 2-, or
3-base changes were required to develop resistance to 1, 2, or 3
drugs applied simultaneously, given that each drug acted on a
different target and that a single base change could generate
resistance to each drug. If influenza variants carrying all possible
single-base changes were generated during the course of an
infection, then there would be included among the population all
possible drug resistant variants that require only a single
nucleotide substitution to generate resistance. However, if only
1% of all possible variants were generated, then there would be a
1% chance that any particular drug resistant variant would be
generated. In this calculation, all base changes are considered to
be equally probable, conforming to the simplifying assumption
that was made to estimate the genetic barrier needed for effective
antiretroviral therapy against HIV infection [23]. Biases in either
the gene in which the mutation occurs (e.g. M2 or NA) or the sites
within these genes are not included in this first model. However,
by using a mutation rate that is 10-fold lower than some reported
values [24,25], we are implicitly correcting for the possibility that
some positions could be 10-fold more mutable. As shown in
Table 1, all possible 1-base changes are expected to be generated
during the course of an acute infection for H3N2 and H5N1
viruses, based on assumptions of the mutational rate for influenza
(see Materials and Methods). The calculation is based on the total
number of virions produced and not the number of infectious
virions produced during a typical infection. Thus, whether a virion
carrying a drug resistant phenotype will be viable, infectious, and
fit enough to grow is not considered. When considering 2-base
change variants, the probability of generating all possible
combinations was reduced to 22% for H3N2 (Table 1) but did
not change for H5N1 (100%). In contrast, when all possible 3-base
changes were considered, the probability was reduced by more
than a million-fold for both H3N2 and for H5N1, so that the
probability of generating a particular triple mutant that could
engender resistance to all three drugs used in a combination
regime was 1.4610
27 for an H3N2 infection and about 7.2610
27
for an H5N1 infection. The exact values of these probabilities
depends on our simplifying assumptions but the general conclusion
that generating a particular triple mutant that would engender
drug resistance to three drugs is an extremely rare event is a robust
conclusion given the influenza mutation rate (see Materials and
Methods). These values for influenza A are similar to the
probability of generating all possible 1-, 2-, and 3-base changes
during the course of a day during chronic HIV infection. Thus, as
in HIV, the likelihood of generating drug resistant influenza A
variants to a 3-drug regimen is dramatically reduced compared to
1- and 2-drug regimens.
Selection of resistant virus variants under serial passage
at fixed concentrations
We then evaluated the emergence of resistant virus upon serial
passage in MDCK cells in the presence of fixed concentrations of
Table 1. Probability of Generating all Possible 1-, 2-, or 3-Base
Mutations in HIV or Influenza A.
Number of Base Changes HIV
1 H3N2
2 H5N1
2
1 100% 100% 100%
2 0.7% 22% 100%
3 0.000007% 0.000014% 0.000072%
The rate at which variants of HIV and influenza A viruses are generated which
contain 1-, 2-, or 3-base substitutions were calculated using a binomial
distribution. Assumptions used for the calculations are provided in Materials
and Methods.
1Per day in chronically infected patients as calculated in [23].
2Per course of infection in otherwise healthy patients.
doi:10.1371/journal.pone.0029778.t001
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double combination, and the TCAD regimen). Drug concentra-
tions were chosen to bracket the clinically relevant concentrations
for all three drugs (Table 2 and Materials and Methods). We
selected MDCK cells for this experiment for two reasons: i) it is not
possible to control the expression of a-2,6-sialyltransferase in
MDCK-SIAT1 cells from lot-to-lot, and any variability in
expression may affect the levels of resistance to OSC; and ii) the
model we are testing is not sensitive to the particular resistance
mutant, so that the advantage of the MDCK-SIAT1 over MDCK
for producing clinically relevant H274Y variants in neuraminidase
does not come into play. We first measured the percentage of
variants with AMT resistance-associated substitutions at the end of
each passage by quantitative allele-specific PCR (qASPCR). The
assays used in this study were specifically designed to detect the
V27A, A30T, and S31N substitutions in M2 which confer
resistance to amantadine. Due to the large number of conditions
tested, data for the multiplicity of infection (MOI) condition
resulting in the greatest percentage of resistant virus variants are
presented, whereas data for all MOI conditions are reported in
Table S1.
Figure 1 shows the percentage of viruses bearing M2 resistance-
associated substitutions at the last passage (passage 5) as a function
of drug concentration under the MOI condition resulting in the
greatest percentage of resistant virus variants. As shown in
Figure 1, treatment with AMT and the AMT/OSC double
combination resulted in high percentages of viruses bearing
amantadine resistance-associated substitutions in M2 (.98%),
with the greatest frequency of resistance occurring at the clinically
relevant concentration (Concentration 3) and 1/3 the clinically
relevant concentration (Concentration 2). In contrast, treatment
with the TCAD regimen resulted in suppression of resistance at all
drug concentrations, such that viruses containing M2 resistance-
associated substitutions never became predominant in the
population (,35%).
Because of the importance of viral load to the absolute number
of resistant variants, viral load was also determined for each
sample on which qASPCR was performed. Viral load for all
samples can be found in Table S1. The no drug control group
ranged from 7.9 to 9.1 log10 copies/mL at passage 5. Under
treatment with AMT alone, the viral load at passage 5 was within
2 log10 copies/mL of the matched no drug control in all conditions
Table 2. Concentrations (mg/mL) of Drugs Used for Serial Passage at Fixed Concentrations.
Drug
Concentration 1
1/96CR
Concentration 2
1/36CR
Concentration 3
CR*
Concentration 4
36CR
Amantadine (AMT) 0.05 0.14 0.43 1.29
Oseltamivir carboxylate (OSC) 0.03 0.10 0.3 0.9
Ribavirin (RBV) 0.14 0.43 1.3 3.9
*CR, clinically relevant (see Materials and Methods).
doi:10.1371/journal.pone.0029778.t002
Figure 1. Percent of Resistant Virus Variants Generated at Passage 5 as a Function of Drug Concentration. Wild type influenza A/
Hawaii/31/2007 (H1N1) virus was passaged five times in MDCK cells, with the concentrations of drugs in each regimen kept fixed in between
passages. The drug concentrations used are given in Table 2 and are discussed in the Materials and Methods. Concentrations 1 to 4 correspond to 1/
9, 1/3, 1, and 3 times the clinically relevant concentration for each drug, respectively. The percent of virus variants bearing resistance-associated
substitutions in M2 channel (V27A, A30T, or S31N) are presented as the mean of triplicate qASPCR reactions with 95% confidence intervals from a
single well of MDCK cells. Concentration 3 represents the clinically relevant concentrations of all three drugs (AMT, OSC, and RBV, see Materials and
Methods).
doi:10.1371/journal.pone.0029778.g001
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copies/mL reduction). For AMT/OSC at Concentrations 1 and 2,
no viral load reduction was seen at any condition at passage 5,
regardless of the percentage of resistance-associated substitutions
present. At Concentrations 3 and 4, the one condition with high
viral load (8.1 log10 copies/mL) at passage 5 also had a high
percentage of resistance-associated substitutions (100%), whereas
conditions which yielded few or no resistant variants (,10%) had
viral load reductions of .5.1 log10 copies/mL compared to
matched no drug control. Treatment with TCAD at Concentra-
tions 1 and 2 in general had little effect on viral load, whereas at
Concentrations 3 and 4 there were reductions in viral load of .3.9
log10 copies/mL compared to the no drug control. Unlike ATM/
OSC, the presence of resistant variants was not correlated with
higher viral loads at any concentration. Thus, treatment with
TCAD was not only associated with a lower percentage of resistant
variants compared to AMT and AMT/OSC, but it also resulted in
a decrease in the total number of resistant virions.
Figure 2 shows percentage of virus variants with AMT
resistance-associated substitutions as a function of passage at the
same four fixed concentrations for the drug regimens which
contained AMT (AMT as a single agent, AMT/OSC double
combination, and the TCAD regimen). Treatment with AMT
alone and the AMT/OSC double combination with Concentra-
tion 2 and Concentration 3 (clinically relevant) resulted in the
rapid selection of AMT-resistant virus variants, which comprised
$50% of the population by passage 3 at Concentration 2, and
.50% of the population by passage 2 at Concentration 3.
Treatment with the TCAD regimen at the same drug concentra-
tions (Concentrations 2 and 3) resulted in sustained suppression of
resistance at all passages, such that viruses containing M2
resistance-associated substitutions never became predominant in
the population at any time point. The lowest concentrations for all
treatment regimens (Concentration 1) resulted in a low frequency
and delayed outgrowth of resistant virus variants across all drug
regimens at later passages. At the highest concentration (Concen-
tration 4), the AMT/OSC double combination and the TCAD
regimen effectively suppressed resistance at all passages, whereas
treatment with AMT alone resulted in the predominance of AMT-
resistant variants by passage 2.
Figure 2. Percent of AMT-Resistant Virus Variants Generated as a Function of Passage Number. Wild type influenza A/Hawaii/31/2007
(H1N1) virus was passaged five times in MDCK cells, with the concentrations of drugs in each regimen kept fixed in between passages. The percent of
virus variants bearing resistance-associated substitutions in M2 (V27A, A30T, or S31N) at each passage are presented as the mean of triplicate qASPCR
reactions with 95% confidence intervals from a single well of MDCK cells. Each panel represents an increase in the concentration of each drug in the
various regimens, with Concentration 3 representing the clinically relevant concentrations of all three drugs (see Materials and Methods). Drug
concentrations are provided in units of mg/mL.
doi:10.1371/journal.pone.0029778.g002
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concentrations was repeated under identical conditions and
produced similar results as those presented here, i.e. treatment
with AMT and AMT/OSC selected for AMT-resistant variants,
whereas treatment with the TCAD regimen resulted in the
sustained suppression of resistance (data not shown).
The supernatants from passage 5 of selected conditions were
then sequenced by the Sanger method at the M2, hemagglutinin
(HA), and NA genes to confirm the results of the qASPCR
analysis, and to identify other substitutions which may confer
resistance which were not detected by qASPCR. For substitutions
in M2, which conferred amantadine-resistance, there was a strong
concordance between the genotype as determined by qASPCR
and the genotype as determined by Sanger sequence analysis. Of
the 14 conditions for which the genotype was determined by both
methods, 11 gave consistent results (Table S2). The discrepancies
in the other three conditions can be attributed to the specific
mutations targeted by the qASPCR assays in this study (only three
of the five codons in M2 known to confer resistance were sampled)
and/or the differences in the sensitivity for detecting minor
populations of the two methods (,25% for Sanger sequencing and
#1% for qASPCR). Additional substitutions were detected at
position 26 and 34 of the M2 gene upon treatment with TCAD
concentration 1 and AMT concentration 4, respectively, which
conferred amantadine resistance [26].
Substitutions in HA were also identified by the Sanger method,
showing HA substitutions at codons 163 (N163T, H3 numbering)
and 165 (S165R) in 9 of 22 and 8 of 22 samples, respectively
(Table S2). The N163T substitution was detected in samples
treated with regimens containing OSC (OSC alone, AMT/OSC,
and TCAD) but not in samples treated with AMT alone, whereas
the S165R substitution was detected in samples treated with any
regimen (AMT alone, OSC alone, AMT/OSC, and TCAD). Both
of the HA substitutions confer high level resistance to OSC and
ZAN, but not AMT (see below). The NA gene was also sequenced
though no substitutions were detected.
Selection of resistant virus variants under serial passage
at escalating concentrations
The selection for resistant virus variants upon serial passage in
MDCK cells under escalating concentrations of drug regimens
(single agents and double and triple combinations) was examined
by monitoring the susceptibility of the virus to each drug after
serial passage. Figure 3 shows the fold increase in concentration of
each drug regimen versus cumulative days in culture (see Table S3
in Supporting Material for more details of the passage history).
The virus was passaged for a total of 22–31 days in the presence of
each drug regimen. For AMT and ZAN, serial passaging was
terminated when the drug concentration reached the TC50
(33 mg/mL for AMT; for ZAN, since the TC50 had not been
previously determined, the TC50 of 118 mg/mL for OSC was used
as the predetermined not-to-exceed concentration).
In the presence of AMT, OSC, and ZAN as single agents, the
virus was able to replicate under increasing drug concentrations at
every passage starting at passage 2 until the last passage. The final
drug concentrations at the last passage were 33 mg/mL for AMT
(2200-fold starting concentration), 30.7 mg/mL for OSC (1024-
fold starting concentration), and 118 mg/mL for ZAN (3933-fold
starting concentration). In the presence of RBV as a single agent,
the highest concentration that resulted in virus-induced cytopathic
effect (CPE) was 96 mg/mL (64-fold starting concentration), at
which point further increases in concentration resulted in the
inhibition of CPE. The virus was passaged for a total of 4 passages
(15 days total) at 96 mg/mL RBV without further increases in drug
concentration.
Figure 3. Passage History of Wild Type Influenza A/Hawaii/31/07 under Escalating Drug Concentrations. Wild type influenza A/Hawaii/
31/2007 (H1N1) virus was passaged in the presence of escalating concentrations of each drug regimen for a total of $25 cumulative days in culture,
or until the drug concentration reached the 50% of the cytotoxic concentration (TC50) of the drug as a single agent.
doi:10.1371/journal.pone.0029778.g003
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highest concentration that resulted in virus-induced CPE was
0.24 mg/mL AMT and 0.48 mg/mL OSC (16-fold the starting
concentration for each drug), at which point further increases in
concentration resulted in the inhibition of CPE. In the presence of
the OSC/ZAN double combination, the virus was able to replicate
under steadily increasing drug concentrations, such that final drug
concentrations at the last passage were 30.7 mg/mL OSC and
30.7 mg/mL ZAN (1024-fold starting concentration of each drug).
In the presence of the TCAD regimen, the highest concentra-
tion that resulted in virus-induced CPE was 0.03 mg/mL AMT,
0.06 mg/mL OSC, and 3.0 mg/mL RBV (2-fold starting concen-
tration for each drug), at which point further increases in
concentration resulted in the inhibition of CPE. The virus was
passaged for a total of 5 passages (22 days total) at this
concentration without further increases in drug concentration.
Phenotypic resistance under serial passage at escalating
drug concentrations
The phenotypic resistance of the viruses in the supernatants
after serial passage in the presence of increasing drug concentra-
tions was determined by monitoring the susceptibility to individual
drugs, and resistance is defined as a shift in the 50% effective
concentration (EC50)o f.5-fold compared to the input virus.
Table 3 provides a summary of the measured EC50 value and fold-
change in EC50 for each drug regimen. Serial passage of the virus
in the absence of drugs (no drug control) resulted in increases of
2.2-fold, 34-fold, 1.4-fold, and 3.3-fold in EC50 to AMT, OSC,
ZAN, and RBV, respectively, relative to the input virus. These
data demonstrate that the virus remained susceptible to AMT and
RBV. The EC50 values of OSC and ZAN varied widely (.40-fold)
between replicate plates (data not shown), and thus no conclusions
regarding the susceptibility of the viruses in the supernatant to
these drugs could be made. However, when individual clones were
plaque purified from the no drug control and tested, the EC50
values for OSC and ZAN were within 0.3- to 0.9-fold of the input
virus (Table 4), indicative that these viruses were sensitive to OSC
and ZAN.
Serial passage in the presence of AMT, OSC, and ZAN as
single agents resulted in resistance to each of these drugs, as
demonstrated by the increases of .43-fold in EC50 values to each
drug relative to the input virus. In contrast, serial passage in the
presence of RBV as a single agent resulted in an EC50 shift of 2.2-
fold relative to the input virus. In the presence the AMT/OSC
double combination, serial passage resulted in a 1.8-fold change in
EC50 for AMT and a 46-fold change in EC50 for OSC, indicative
of resistance to OSC but not AMT. Serial passage in the presence
of OSC/ZAN double combination resulted in a .22-fold change
in EC50 values to both drugs, indicative that resistance emerged to
both drugs. For the TCAD regimen, serial passage resulted in a 2-
fold, 1371-fold, and 3.4-fold increase in EC50 values to AMT,
OSC, and RBV, respectively. These data indicate resistance was
generated to OSC but not to AMT or RBV.
Effects of substitutions on drug susceptibility
The presence of mutations in the M2, HA, and or NA genes of
viruses in the supernatant after serial passage in the presence of
escalating drug concentrations were detected by Sanger sequenc-
ing. A summary of amino acid substitutions detected in
supernatants is provided in Table 3. Genotypic analysis of the
supernatant from the no drug control identified the D190N amino
acid substitution in HA. Although an asparagine at position 190 in
HA marks a change in sequence from the input virus, the presence
of asparagine at position 190 is consistent with the published
Table 3. Summary of Phenotype and Genotype of Supernatants after Serial Passage under Escalating Drug Concentrations.
Regimen EC50 (mg/mL)
a Fold Change in EC50 vs Input Virus Substitution Detected
b (Protein)
No Drug Control AMT=0.08960.076 2.2 D190N (HA)
OSC=1.261.6 34
ZAN=1.161.5 1.4
RBV=5.361.6 3.3
AMT AMT=.33 .800 L26F (M2)
OSC OSC=13611 371 S165R (HA)
ZAN ZAN=33628 43 S165R (HA)
RBV RBV=3.662.4 2.2 –
AMT/OSC AMT=0.07260.039 1.8 S165R (HA)
OSC=1.661.8 46
OSC/ZAN OSC=1067.4 286 S165R (HA)
ZAN=17612 22
TCAD AMT=0.7860.027 2.0 N163T (HA)
OSC=48634 1371
RBV=5.561.5 3.4
Wild type influenza A/Hawaii/31/07 (H1N1) virus was passaged in the presence of escalating concentrations of each drug regimen for a total of $25 cumulative days in
culture, or until the drug concentration reached the 50% of the cytotoxic concentration (TC50) of the drug as a single agent. Each drug regimen was tested starting at 1/
8
th the EC50 of each drug as a single agent. The drug concentration was increased 1X, 2X, or 4X at each passage starting at passage 2, depending on whether virus-
induced cytopathic effect (CPE) was apparent during the passage. Phenotypic testing using neutral red assay in MDCK cells was performed on the supernatants from
each regimen to determine the susceptibility to each drug as a single agent after serial passage. In addition, the supernatant from selected passages from each regimen
was sequenced by the Sanger method at the M2, hemagglutinin (HA), and/or neuraminidase (NA) genes to detect the presence of mutations.
aEC50 values are the mean of 6 replicate wells from two plates with standard deviations.
bAmino acid positions in HA are designated using universal H3 numbering [42].
doi:10.1371/journal.pone.0029778.t003
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virus clones purified from the no drug control revealed that the
EC50 values for AMT, OSC, RBV, and ZAN were within 0.3- to
1.4-fold of the input virus, suggestive that the D190N substitution
does not confer reduced susceptibility. No substitutions were
identified in M2 or NA for the no drug control.
Genotypic analysis of supernatants passaged in the presence of
AMT, OSC, and ZAN as single agents identified single amino acid
substitutions – L26F in M2 in the case of AMT, and S165R in HA
in the case of OSC and ZAN. Phenotypic analysis using purified
virus clones confirmed that these substitutions conferred high level
resistance to these drug regimens (Table 4). The purified virus
clone bearing the L26F substitution showed an increase of .800-
fold in EC50 value for AMT as compared to the input virus.
Similarly, the purified virus clone bearing the S165R substitution
showed an increase of 330-fold in EC50 value for OSC and 64-fold
in EC50 value for ZAN as compared to the input virus. In contrast,
no amino acid substitutions were identified in the supernatants
passaged in the presence of RBV (for M2, HA, or NA), and virus
clones isolated from the RBV regimen remained susceptible to
RBV (data not shown).
Serial passage in the presence of escalating concentrations of
AMT/OSC and OSC/ZAN resulted in the selection of viruses
bearing a single amino acid substitution (S165R in HA) which
conferred high level resistance to OSC and ZAN but not to AMT
(Tables 3 and 4). For the AMT/OSC regimen, a second
substitution in HA (Y178F) was identified at passage 5 after 21
days in culture (Table S3). However, it was not possible to isolate
virus clones bearing the Y178F substitution, and thus the effect of
this substitution on drug susceptibility is unknown.
In the presence of escalating concentrations of the TCAD
regimen, serial passage resulted in the emergence of viruses
bearing the N163T substitution in HA. The N163T substitution
conferred resistance to OSC and ZAN, but not to AMT or RBV.
The EC50 value of OSC and ZAN against the purified virus clone
bearing the N163T substitution was 560- and 140-fold higher,
respectively, than that of the input virus. In contrast, the EC50
values for AMT and RBV against the purified N163T variant
were within 0.7-fold of the EC50 values of the input virus
(Table 4).
Contribution of each drug in TCAD to the suppression of
resistance
The contribution of each of the three drugs in the TCAD
regimen – AMT, OSC, and RBV – to the suppression of
resistance was examined by quantifying the frequency of virus
breakthrough under selective pressure from each double combi-
nation and the TCAD regimen using fixed clinically relevant
concentrations of two drugs and varying concentrations of each
drug as the third drug.
Figure 4 shows the percentage of wells exhibiting virus
breakthrough as a function of increasing concentrations of each
titrated third drug. The results show that treatment with all three
double combinations – OSC/RBV, AMT/RBV, and AMT/OSC
– resulted in a high percentage of wells having virus breakthrough
(75–100%). Titration of each drug into the appropriate double
combination resulted in the concentration-dependent decrease in
the number of wells with virus breakthrough. A statistical analysis
of the number of wells with virus breakthrough demonstrated that
each drug made a statistically significant contribution to the
suppression of virus breakthrough at clinically achievable concen-
trations: AMT at 0.3 mg/mL and above, OSC at 0.15 mg/mL and
above, and RBV at 0.9 mg/mL and above (Table 5). When the
supernatants from wells with virus breakthrough were sequenced
by the Sanger method, there was a high concordance between
virus breakthrough and the presence of resistance-associated
substitutions in M2, HA, and /or NA (Table 5). Specifically, all
the substitutions detected occurred at positions that have been
demonstrated to confer resistance to amantadine (amino acid
positions 26, 27, 30, 31, and 34 in M2) and/or oseltamivir (274 in
NA, and 163 and 165 in HA).
Discussion
In this report, we present a model system and process to
evaluate the effects of drug combinations on the emergence of
resistance. While the experimental conditions utilized may not
reflect conditions in vivo, they provide a basis to compare the effects
of different drug regimens under similar conditions. The use of
mathematical models, multiple methods to generate resistance,
and multiple methods to quantitate the effects of antiviral drug
Table 4. Susceptibility of Virus Clones to AMT, OSC, RBV and ZAN as Single Agents.
AMT OSC RBV ZAN
Substitution
(Regimen) EC50 (mg/mL)
a
Fold
increase
relative to
input virus EC50 (mg/mL)
a
Fold
increase
relative to
input virus EC50 (mg/mL)
a
Fold
increase
relative to
input virus EC50 (mg/mL)
a
Fold
increase
relative to
input virus
Input virus 0.04060.013 - 0.03560.014 - 1.660.18 - 0.7760.47 -
Wild type (NDC)
b 0.05560.004 1.4 0.03060.006 0.9 1.260.13 0.8 0.2460.064 0.3
M2-L26F (AMT) .33 .800 0.00560.001 0.14 0.6560.064 0.4 0.07860.046 0.10
HA-S165R (OSC)
c 0.07860.059 2.0 1162.8 330 2.160.22 1.3 49621 64
HA-N163T (TCAD)
c 0.02960.001 0.7 2061.9 560 1.160.16 0.7 104628 140
Wild type influenza A/Hawaii/31/07 (H1N1) virus was passaged in the presence of escalating concentrations of each drug regimen, and the supernatant from selected
passages from each regimen was sequenced by the Sanger method at the M2, hemagglutinin (HA), and/or neuraminidase (NA) genes to detect the presence of
mutations. Six virus clones were isolated from each regimen (from the latest passage that yielded viable plaques) and were sequenced at M2, HA, and NA to confirm
that the genotype of the clone matched that of the supernatant. The susceptibility of clones bearing representative substitutions to AMT, OSC, RBV, and ZAN was tested
using neutral red assay.
aEach drug was tested using two plates, with 3 replicate wells per plate. EC50 values are the mean of duplicate plates with standard deviations.
bNo drug control passaged in parallel.
cAmino acid positions in HA are designated using universal H3 numbering [42].
doi:10.1371/journal.pone.0029778.t004
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of single and combination drug therapies on the virus population.
The process and experimental designs described herein may
provide a generalizable strategy for the optimization of drug
combinations and concentrations to suppress resistance in other
viral diseases. The results from all the methods employed
consistently demonstrated that a combination of three drugs was
superior to single or dual agents at suppressing resistance in
influenza A viruses.
There is currently little data on the effects of antiviral
combinations on the emergence of resistance in influenza.
Ilyushina et al. [27] tested the effects of the double combination
of OSC and AMT on the development of resistance in three
influenza A subtypes (H1N1, H3N2, and H5N1) in vitro. In that
study, serial passage at increasing concentrations of AMT or OSC
alone resulted in high virus yield at the 5
th passage, and the viruses
from the supernatant of the last passage bore substitutions in M2
(AMT-treated) and HA (OSC-treated). In contrast, treatment with
the AMT/OSC double combination resulted in low or undetect-
able viral titer, and no substitutions in either M2 or HA were
identified at the higher concentrations of both drugs. One caveat is
that the study utilized supra-physiological concentrations of AMT.
The lowest concentration of AMT used was 10 mM (1.9 mg/mL),
which is 3- to 4-fold higher than what could be achieved in plasma
based on labeled doses (see Materials and Methods), and thus the
results may not be clinically meaningful. In a clinical study, Ison et
al. [28] reported the use of nebulized ZAN in combination with
rimantadine in adults hospitalized with influenza infection.
Although the study was terminated early and was underpowered,
the authors noted that 2 of the 21 patients receiving rimantadine
monotherapy developed rimantadine resistant virus variants with
A30T and S31N substitutions in M2, whereas 0 of the 20 patients
treated with rimantadine in combination with ZAN developed
resistance to either drug.
To first determine the number of drugs required in a regimen to
suppress the emergence of resistance in influenza A virus, we
calculated the probability of an infecting drug-sensitive virus
acquiring all the necessary mutations to escape the effects of 1, 2,
or 3 drugs. The results predict that a three-drug regimen would
have significant therapeutic benefit over one- and two-drug
regimens as some or all of the drugs are likely to remain active
during the course of treatment. However, if a fit 2-base change
variant was generated early in infection, it could further acquire an
additional mutation. Our calculation ignores this possibility and
thus the dangers of drug resistance emergence on therapy could be
greater than estimated (Table 1). While these results need to be
confirmed in clinical trials for influenza, the benefit of a three-drug
regimen over one- and two-drug regimens have been demonstrat-
ed in clinical trials in HIV [29,30,31] as well as in clinical practice
[32].
We then quantified the levels of resistance to AMT after serial
passage under pressure from fixed concentrations of drugs, using
qASPCR to detect and quantitate markers of resistance. As
resistance to AMT is not complicated by assay discrepancies, i.e.
substitutions in M2 confer resistance to AMT both in cell culture
assays and in vivo, the use of qASPCR to quantitate AMT
resistance may provide a better representation of the total
resistance under each treatment regimen. As expected, resistance
to AMT as a single agent emerged rapidly. Surprisingly, the
AMT/OSC double combination was not superior to AMT alone
at suppressing resistance to AMT; treatment with AMT/OSC
paralleled treatment with AMT alone in the rate in which
resistance emerged and the percentage of resistant variants in the
population (Figure 2). In contrast, the TCAD regimen was
effective at suppressing resistance to AMT at all concentrations
tested. It should be noted that Abed et al. have shown that variants
bearing substitutions in M2 do not have reduced fitness [33]. At
Concentration 3 where maximum resistance was observed in the
AMT and AMT/OSC conditions, variants with high level
resistance to AMT also emerged under treatment with the TCAD
regimen but did not out-compete the wild type population,
suggesting that a single substitution in M2 did not confer a
selective advantage. Furthermore, the observation that there was a
stronger selective pressure for AMT-resistant variants under
treatment with the AMT/OSC double combination than the
TCAD regimen clearly shows that the addition of RBV to AMT/
OSC double combination had a profound impact on the
suppression of AMT resistance. We have previously shown that
AMT contributed to the antiviral activity of the TCAD regimen
against AMT-resistant influenza A viruses at clinically achievable
concentrations where AMT had no activity as a single agent [21].
The lack of a strong selective advantage for variants with M2
substitutions under TCAD treatment may be partially due to the
enhanced activity of AMT as part of the TCAD regimen against
the AMT-resistant variants.
Sanger sequence analysis of the supernatants from the last
passage of the fixed combination study revealed the presence of
substitutions in M2 and HA. The generation of variants with HA
substitutions as the result of serial passage in the presence of NAIs
have been documented previously [11,12,27], and resistance to
NAIs in vitro may arise as the result of a lower affinity for cellular
receptors with a concomitant decrease in dependence on NA for
release from the cell surface [11,34]. It should be noted that while
HA substitutions may confer resistance to NAIs in cell culture
assays, these substitutions do not necessarily confer reduced
susceptibility when evaluated using neuraminidase enzyme
inhibition assays or in in vivo models [35]. While substitutions in
HA which confer resistance to NAIs may be a phenomenon
specific to cell culture assays, they are relevant in this context as
they represent a pathway to resistance which can be used to
evaluate the effects of different drug regimens.
In this study we demonstrated that, under serial passage at
escalating concentrations, the TCAD regimen imposed a high
Figure 4. Each Drug in TCAD Contributes to the Suppression of
Virus Breakthrough. MDCK cells in 96-well plates were infected with
influenza A/Hawaii/31/2007 (H1N1) virus in the presence of a
combination of two drugs at fixed concentrations with varying
concentrations of the third drug, using 12 replicates for each condition.
The fixed concentrations of the double combinations were 0.30 mg/mL
OSC and 0.60 mg/mL RBV, 0.6 mg/mL AMT and 0.6 mg/mL RBV, or
0.6 mg/mL AMT and 0.3 mg/mL OSC. Following 5 serial passages, the
number of wells for each condition having virus breakthrough, defined
as .50% cytopathic effect, was determined by neutral red uptake.
doi:10.1371/journal.pone.0029778.g004
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single substitution (N163T in HA) that emerged under TCAD
treatment conferred resistance to OSC, but not to AMT and
RBV, and thus was not adequate to allow the virus variants to
escape the effects of the other drugs in the TCAD regimen
(Tables 3 and 4). The AMT/OSC regimen also imposed a higher
barrier to resistance compared to the single agents and double
NAI combination (OSC/ZAN), in which a single substitution
conferred resistance to OSC but not to AMT. We did not evaluate
the genetic barrier to resistance for RBV in this study, as
phenotypic resistance to RBV was not detected (Table 3). While
the virus was able to replicate at up to 96 mg/mL RBV in the serial
passage experiment, which is 10- to 20-fold higher than the EC50
of RBV, it should be noted that each passage had a duration
of up to 6 days in culture, whereas the incubation for EC50
determination was 3 days. Thus, it is possible that replication by
susceptible viruses is capable of causing CPE at higher RBV
concentrations after 6 days, which would not be detected by EC50
determination after 3 days. The lack of resistance to RBV is not
surprising, given that resistance to RBV is rare in other viruses and
clinical resistance to RBV in HCV has not been clearly
demonstrated [36,37]. To our knowledge, resistance to RBV in
influenza viruses has not been identified.
Finally, we also examined the contribution of each drug in the
TCAD regimen to the suppression of virus breakthrough and
resistance using 12 replicate wells per condition, which allowed us
to measure the frequency of virus breakthrough. Statistically
significant reductions in virus breakthrough were observed in all
cases where each drug was titrated as the third drug into the
double combinations under clinically achievable concentrations.
Thus, each drug in the TCAD regimen made a concentration-
dependent contribution to the suppression of resistance. Impor-
tantly, these data enable the determination of the optimal
concentrations of each drug in the TCAD regimen for maximal
suppression of resistance.
These data also help establish a paradigm for an integrated
process coupling mathematical modeling with multiple experi-
mental designs to better understand the relationship between viral
dynamics and evolution of resistance under combination drug
pressure. Future work should attempt to i) confirm these findings
Table 5. Virus Breakthrough and the Presence of Resistance-Associated Substitutions as a Function of the Concentration of the
Third Drug in TCAD.
Concentration of Third
Drug (mg/mL)
No. Wells with Virus
Breakthrough P value
a No, Wells with Substitutions
b Amino Acid Substitutions
c
Titration of amantadine into fixed concentrations of OSC/RBV
0 12 – 11 M2: L26F; HA: N163T, S165R
0.1 11 0.761 11 M2: V27A, A30T, S31N, G34E;
NA: H274Y; HA: N163T, S165R
0.3 6 0.034 5 M2: V27A, A30T, S31N; NA: H274Y
0.6 1 ,0.001 1 M2: G34E; HA: N163T
0.9 3 0.001 3 M2: S31N; HA: N163T, S165R
1.2 2 ,0.001 2 M2: S31N; HA: N163T
Titration of oseltamivir carboxylate into fixed concentrations of AMT/RBV
0 12 – 11 M2: V27A, A30T, S31N, G34E
0.075 9 0.109 8 M2: L26F, V27G, G34E;
HA: N163T, S165R
0.15 3 ,0.001 3 M2: S31N; HA: S165R
0.3 3 ,0.001 3 M2: L26F, V27A, G34E; HA: N163T
0.6 1 ,0.001 1 M2: S31N
1.2 1 ,0.001 1 M2: S31N
Titration of ribavirin into fixed concentrations of AMT/OSC
0 8 – 7 M2: V27G; V27A, S31N; HA: N163T
0.3 8 0.6667 8 M2: V27A, A30V; HA: N163T, S165R
0.6 3 0.0498 0
0.9 1 0.0047 1 M2: S31N
1.2 0 0.0007 0
2.4 0 0.0007 0
MDCK cells in 96-well plates were infected with influenza A/Hawaii/31/2007 (H1N1) virus in the presence of a combination of two drugs at fixed concentrations with
varying concentrations of the third drug, using 12 replicates for each condition. The fixed concentrations of the double combinations were 0.30 mg/mL OSC and
0.60 mg/mL RBV, 0.6 mg/mL AMT and 0.6 mg/mL RBV, or 0.6 mg/mL AMT and 0.3 mg/mL OSC. Following 5 serial passages, the number of wells for each condition having
virus breakthrough, defined as .50% cytopathic effect (CPE), was determined by neutral red uptake.
aStatistical analysis of the number of wells with virus breakthrough at each concentration of third drug compared to no third drug was performed using the Fisher’s
exact test.
bThe supernatants from wells with virus breakthrough were analyzed by Sanger sequencing at the M2, HA, and NA genes to determine the presence of resistance-
associated mutations.
cSubtitutions are listed if they were detected in any well by Sanger sequencing. Amino acid positions for NA and HA are presented using N2 and H3 numbering,
respectively.
doi:10.1371/journal.pone.0029778.t005
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of drug combinations and barriers to resistance in wild type and
previously resistant viruses, iii) and extend these findings to other
rapidly mutating pathogens for which combination approaches are
desperately needed.
Materials and Methods
Modeling mutation in HIV and influenza virus
Starting from a drug-sensitive or wild-type virus the number of
HIV and influenza A viruses that contain 1-, 2-, or 3-base
substitutions were calculated using a binomial distribution where
we assumed: 1) the mutation rate for influenza A virus is 2610
26
per nucleotide per infectious cycle [38]; and 2) the number of bases
in the influenza A genome is 1.4610
4. Much higher mutation
rates have also been reported [24,25] and thus we are being
conservative in estimating the error rate involved in RNA
replication. We further assumed that 3) there are 4610
8 epithelial
cells in the upper respiratory tract [39], 25% of which become
infected before influenza is cleared [40]; 4) each infected cell
produces ,5000 virions, so that the total number of virions
produced during infection is ,5610
11 (higher levels of viral
production per cell have been reported by Mohler et al. [41] so
this estimate may be conservative); and 5) for H5N1 viruses, it is
assumed that the infection can spread to the lower respiratory tract
and infect 5-fold more cells. Comparing the number of virions
produced carrying 1, 2, or 3 mutations with the total number of
possible variants yields the entries in Table 1. The calculation for
HIV is taken from [23].
Antiviral compounds
Amantadine (AMT) was obtained from Moehs Catalana, S.I.
(Barcelona, Spain). Oseltamivir carboxylate (OSC, the active
metabolite of oseltamivir) was obtained from Charnwood
Molecular (Loughborough, United Kingdom) through synthesis
via the Nboc-protected acid from oseltamivir phosphate. Zana-
mivir (ZAN) was obtained from Haorui Pharma-Chem, Inc.
(Edison, NJ). Ribavirin (RBV) was purchased from BASF
Orgamol Pharma Solutions SA (Evionnaz, Switzerland).
Influenza virus preparation
The virus used for this study was wild type influenza type A/
Hawaii/31/2007 (H1N1) and was obtained from the Centers for
Disease Control and Prevention (Atlanta, GA). The CDC stock
was sequentially passaged two times in MDCK cells to produce a
single virus stock. This virus stock was then aliquoted and stored at
280uC and used for antiviral studies. Sanger sequencing of the
M2, HA, and NA genes from the virus stock revealed identity of
100% in the M2 protein, 99% in the HA protein, 100% NA
proteins with published sequences (reference EU516164.1 for M2,
EU516078.1 for HA, and EU516128.1 for NA). The HA protein
had a single amino acid change (N190D, H3 numbering [42])
compared to the published sequence.
Cell preparation
MDCK cells (Madin Darby canine kidney cells, ATCC cat.
no. CCL-34) were grown in 150 cm
2 flasks in MEM/EBSS
medium (Hyclone Laboratories, Logan, UT) and 5% heat
inactivated fetal bovine serum (Hyclone Laboratories) from a
frozen aliquot of a working cell bank originating from the ATCC
stock and the lineage replaced every two months. Within this time
frame the number of cell passages is no more than 10 passages
beyond the ATCC stock.
On the day preceding the experiment, the cells were removed
from the 150 cm
2 flask by trypsinization using 0.25% trypsin with
0.2 g/L EDTA (Hyclone Laboratories), and measured for count
and viability by hemacytometer reading in 0.4% trypan blue
(Sigma-Aldrich, St. Louis, MO). MDCK cells were resuspended to
4610
5 cells per mL in tissue culture medium (specified above) and
added to 6-well or 96-well plates as appropriate. The plates were
covered with a plate cover and incubated at 37uC and 5% CO2
overnight to allow for cell adherence. Prior to infection, the
monolayers were washed with MEM/EBSS to remove residual
fetal bovine serum.
Serial passage at fixed concentrations of drug regimens
Each well of the 6-well plates contained 4.0 mL of test solution
[50 mg/mL gentamicin (Sigma-Aldrich), 1 mg/mL EDTA (Sigma-
Aldrich), and 10 U/mL trypsin (Sigma-Aldrich) in MEM/EBSS
medium] with the appropriate virus dilution with or without
drug(s). Briefly, the cells were incubated in the presence of the test
solution for 15 minutes at 37uC and 5% CO2, and were washed
twice with 2 mL of pre-warmed medium containing the
appropriate drug regimen to remove unbound viruses, and then
replenished with 4 mL pre-warmed medium containing drug and
incubated for 3 days at 37uC and 5% CO2. After day 3, the cells
were scraped off the well and collected along with the supernatant,
briefly sonicated in 30 second bursts to release cell associated
virus, and then aliquoted and stored at 280uC for subsequent
serial passage. Each condition (drug regimen, concentration, and
MOI) was tested in a single well of a 6-well plate.
Virus was passaged using three different MOIs (0.1, 0.01, and
0.001) in the presence of fixed concentrations of each drug
regimen for a total of 5 passages, with each passage having a
duration of 3 days. After each passage, the virus titer was
determined for each condition (drug regimen, concentration and
MOI) by end point titration as previously described [22] and the
virus was diluted to achieve targeted MOIs for the next passage. If
the titer was too low to achieve the targeted MOI, 0.4 mL of the
undiluted cell preparation from the preceding passage was used to
infect cells at the next passage. Subsequent infections were
performed as described above.
The drug regimens tested included AMT and OSC as single
agents, AMT/OSC in double combination, and the TCAD
regimen. Each drug regimen was tested at four concentrations that
bracketed the predicted average human plasma concentrations
(Cave) of each drug, with double and triple combination regimens
tested as fixed ratios of drugs that are the same concentrations as
the single agent regimens. Based on pharmacokinetic data in
humans (manuscript in preparation) and simulation (data not
shown), the labeled dose of 100 mg twice a day for amantadine,
75 mg twice a day for oseltamivir phosphate, and 600 mg twice a
day for ribavirin is expected to produce a Cave of 0.43 mg/mL for
AMT, 0.3 mg/mL for OSC (oseltamivir carboxylate, the active
metabolite), and 1.3 mg/mL for RBV in the first 10 days.
Concentrations of drug used for serial passage at fixed concen-
trations are provided in Table 2.
The percentage of resistance-associated mutations in a sample
was determined by allele-specific real-time PCR (ASPCR) using
TaqManH assays that detected the V27A, A30T, and S31N
substitutions in M2 for amantadine resistance. ASPCR was
performed at each passage and for each condition. Sanger
sequence analysis of the M2, NA, and HA genes were performed
on a subset of samples to confirm the ASPCR results and to
determine whether additional mutations occurred at codons not
monitored by the ASPCR (see below). For experiments with serial
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performed on supernatants from passage 5.
Serial passage at escalating concentrations of drug
regimens
MDCK cells were seeded into 6-well plates in a volume of 3 mL
and the monolayers were washed with MEM/EBSS to remove
residual fetal bovine serum as described above. The virus stock
(influenza A/Hawaii/31/2007 (H1N1)) was added to obtain a
final in-well initial MOI of 33610
26 CCID50/cell. The assay
plates were covered with a plate cover and incubated for
15 minutes at 37uC and 5% CO2 to allow virus adsorption. The
supernatant was then removed and the cells were washed twice
with 2 mL of pre-warmed (37uC) assay medium containing the
appropriate drug regimen and replenished with 4 mL of assay
medium containing the appropriate drug regimen.
The drug regimens tested include AMT, OSC, ZAN, and RBV
as single agents; the double combinations of AMT/OSC and
OSC/ZAN; and the TCAD regimen. The starting concentrations
for each drug regimen was 1/8
th the EC50 of each drug as a single
agent as determined previously (data not shown). Single agents
were tested at starting concentrations of 0.015 mg/mL AMT,
0.03 mg/mL OSC, 0.03 mg/mL ZAN, or 1.5 mg/mL RBV; the
AMT/OSC double combination at 0.015 mg/mL AMT plus
0.03 mg/mL OSC; the OSC/ZAN double combination at
0.03 mg/mL OSC plus 0.03 mg/mL ZAN; and the TCAD
regimen at 0.015 mg/mL AMT, 0.03 mg/mL OSC, and 1.5 mg/
mL RBV. The virus was passaged once at the starting
concentration for each drug regimen. At the second passage, the
supernatant was diluted 1:1000 in MEM/EBSS and 100 mL of the
diluted supernatant from each regimen was used to infect 3 wells
containing drug concentrations that were 1-fold, 2-fold, and 4-fold
the drug concentration used in the first passage. At the end of the
second passage, the supernatant from the highest concentration of
drug that achieved $50% cytopathic effect (CPE, measured using
neutral red uptake as described below) was used to infect three
wells containing drug concentrations that were 1-fold, 2-fold, and
4-fold the highest concentration that achieved $50% CPE in
passage 2. Each passage had a duration of #6 days: the cell
monolayers were examined everyday for the presence of CPE, and
on the day in which $50% CPE was observed for a well, the
supernatant was collected and stored at 280uC. This procedure
was repeated for all subsequent passages. Passaging was continued
until the drug concentrations reached the 50% cytotoxic
concentration (TC50) for each drug as a single agent (33 mg/mL
for AMT, 118 mg/mL for OSC, and 677 mg/mL for RBV) or the
virus had spent $25 days cumulatively in culture in the presence
of drugs, whichever came first.
The susceptibility to AMT, OSC, ZAN, and RBV, was
performed on the supernatants from each regimen (see below).
Drug susceptibility testing was performed using the supernatants
from the latest passage that yielded a sufficiently high virus titer to
allow dilution of the drug in the supernatant to a concentration
that did not interfere with the susceptibility assay ($1000-fold
dilution). In addition, phenotypic analyses were performed on
selected clones bearing representative amino acid substitutions
identified from Sanger sequencing to determine the effects of the
substitution on drug susceptibility.
Sanger sequence analysis of the M2, NA and HA genes were
performed on supernatants from passage 3 and the last passage for
each drug regimen. If a mutation was detected, the supernatants
from additional passages were analyzed by the Sanger method to
identify the first appearance of the mutation. For each regimen, six
virus clones were obtained by plaque purification and were
sequenced to confirm that the genotype matched the genotype of
the supernatant. The clones were obtained from the latest passage
that yielded plaques. Drug susceptibility testing was performed on
selected clones to determine the effects of the mutation on drug
susceptibility.
Contribution of each drug in TCAD to the suppression of
viral breakthrough
The contribution of AMT, OSC, and RBV to the suppression
of resistance under selective pressure from double combinations
and the TCAD regimen was determined by passaging the virus
five times in MDCK cells in the presence of double combinations,
with increasing concentrations of a third drug titrated into the
double combinations. Briefly, MDCK cells plated in 96-well
microtiter plates (8610
4 cells/well) were incubated with influenza
virus and a double combination of 0.30 mg/mL OSC and
0.60 mg/mL RBV, 0.6 mg/mL AMT and 0.6 mg/mL RBV, or
0.6 mg/mL AMT and 0.3 mg/mL OSC. These concentrations
represent the average plasma concentrations for AMT, OSC, and
RBV based on the doses of each drug (75 mg AMT three times
day, 75 mg oseltamivir phosphate three times a day, and 200 mg
RBV three times a day) used in a pilot Phase 1b study of TCAD
therapy in immunocompromised patients (manuscript in prepara-
tion). The third drug was titrated as follows: AMT was titrated at
0, 0.1, 0.3, 0.6, 0.9, and 1.2 mg/mL into the OSC/RBV double
combination, OSC was titrated at 0, 0.075, 0.15, 0.3, 0.6, and
1.2 mg/mL into the AMT/RBV double combination, and RBV
was titrated at 0, 0.3, 0.6, 0.9, 1.2, and 2.4 mg/mL into the AMT/
OSC double combination. Each condition was tested in 12
replicates. After 3 days incubation, 1 or 10 mL of the supernatant
from each well was transferred to a fresh well of uninfected
MDCK cells and incubated for an additional 3 days in the
presence of drugs. This process was repeated for a total of 5
passages. After the 5th passage, the virus induced CPE in each well
was measured by neutral red staining. Virus breakthrough was
defined as wells having greater than 50% CPE. Sanger sequence
analysis of the M2, HA, and NA genes was performed on the
supernatant of each well having greater than 50% CPE to detect
the presence of resistance-associated substitutions.
Quantitative Allele-Specific Real-Time PCR (ASPCR)
Quantitative ASPCR (qASPCR) was performed in 10 ml
reaction volumes in PRISM
TM 384-well Clear Optical Reaction
Plates (Applied Biosystems, Foster City, CA) as previously
described [43]. Briefly, in each 10 ml reaction, 1 ml of template
was added to 9 ml of qPCR reaction mix containing 900 nM of
each Forward and Reverse primer 225 nM of the appropriate
TaqManH MGB probe, 16TaqMan Universal PCR Master Mix
(Applied Biosystems), and molecular-grade water (Promega Corp.
Madison, WI). Separate reactions were carried out with either the
wild-type or the mutant allele-specific primer (sequences for
primers and probes are provided in [43]). Amplification and real-
time fluorescence detections were performed on the 7900HT Real
Time PCR System (Applied Biosystems) using the following PCR
conditions: 3 min at 50uC for UNG treatment, 10 min at 95uC for
Taq Polymerase activation, 40 cycles 15 s at 95uC for denatur-
ation and 1 min at 60uC for annealing and extension. Using a
constant threshold of 0.2 and an automatic baseline, a Ct value
was obtained for each reaction in the Sequence Detection Systems
v2.3 software (Applied Biosystems). Percentages of mutation
present in the population were calculated from the delta Ct value
using plasmids containing an insert of wild-type or mutant DNA
sequence-allele plasmid templates as standards. Each well was
initially analyzed by all ASPCR assays (V27A, A30T, and S31N
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detected at $1% of the population in more than one passage for a
given condition (drug regimen, concentration, and MOI), then
ASPCR analysis was repeated using triplicate reactions for all
passages for that condition for more accurate quantification.
Sanger sequence analysis
Sanger sequencing was performed on regions of the M2, HA,
and NA genes containing previously identified antiviral resistance-
conferring single nucleotide mutations. Sequence analysis was
restricted to progeny derived from A/Hawaii/31/2007 (GenBank
accession numbers EU516078.1, EU516139.1, and EU516164.1).
No new sequence data were generated as a result of this study.
Custom primer pairs targeting the NA, HA, and M2 genes were
used for the PCR and cycle sequencing. Initial PCR reactions with
1 ml cDNA template in 14 ml master mix composed of 16 Taq
Polymerase PCR Buffer (Invitrogen), 3 mM MgCl, 3 mM dNTP’s,
200 nM primers, and 1 U Platinum Taq Polymerase (Invitrogen).
PCR conditions on Biorad’s DNA Engine Thermocycler were
initial denaturation of 95uC for 5 minutes, followed by 35 cycles
of: 95uC for 1 minute, 59uC for 30 seconds, 72uC for 1 minute,
and a final extension of 72uC for 7 minute.
Applied Biosystems’ Big Dye Terminator Kit v3.1 and 2.0 mM
primers (same primers as initial PCR) were used in 10 ml cycle
sequencing reactions consisting of 1 ml DNA template in 9 ml
mastermix. Cycle sequencing was executed as: 96uC for 1 minute
followed by 15 cycles of: 96uC for 10 seconds, 50uC for 5 seconds,
60uC for 1 minute 15 seconds, then 5 cycles of: 96uC for
10 seconds, 50uC for 5 seconds, 60uC for 1 minute 30 seconds,
and ending with 5 cycles of: 96uC for 10 seconds, 50uC for
5 seconds, 60uC for 2 minute. Qiagen’s DyeEx 96 kit was used for
dye removal and samples were analyzed on Applied Biosystems’
3130xl Genetic Analyzer (36 cm array, Pop7 polymer). Sequences
were analyzed for mutations at the codons of interest in Applied
Biosystems’ Sequencing Analysis v5.2 and DNASTAR Lasergene
v8.0.
The sequences of the primers used are provided below (59R39),
where Y represents a pyrimidine base (C or T), R represents a
purine base (A or G), and M represents either A or C:
M2: Forward – CYAGCACTACAGCTAAGGCTATGGA-
GCA
Reverse – CATCCACAGCAYTCTGCTGTTCCT
NA: Forward – CTGGAAGTCAAAACMACACTGGAA-
TATGC
Reverse – CTCCATCAACAGTCACTGGATTR-
CAGC
HA: Forward – GAGAATGGAACATGTTACCCAGGG
Reverse – CTGATCCAAAGCCTCTACTCAGTGC
Phenotype Analysis of Supernatants and Virus Clones
Susceptibility to antiviral drugs was determined as previously
reported [21,22]. Briefly, MDCK cells plated in 96-well microtiter
plates (8610
4 cells/well) were incubated with influenza virus and
either AMT (0.00032, 0.001, 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0,
3.2, 10, 32, 100 mg/mL), OSC (0.001, 0.0032, 0.01, 0.032, 0.1,
0.32, 1.0, 3.2, 10, 32, 100, 320 mg/mL), ZAN (0.001, 0.0032, 0.01,
0.032, 0.1, 0.32, 1.0, 3.2, 10, 32, 100, 320 mg/mL), or RBV
(0.001, 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.2, 10, 32, 100,
320 mg/mL) for three days. Virus-induced CPE was determined
by measuring cell viability by staining with neutral red dye and
measuring the optical density at 540 nm. The spectrophotometric
readings were collected electronically and imported into Graph-
Pad Prism 5 software for four-parameter curve fit analysis. Two
replicate plates were run on two separate days, with 3 replicate
wells on each plate, and the data for each plate are presented
along with the mean of all four plates.
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